#Germany #Munich #gene therapy #Minaris #GMP Facility

Minaris Advanced Therapies Unveils Cutting-Edge GMP Facility in Munich

In a significant leap forward for the biopharmaceutical industry, Minaris Advanced Therapies has announced the inauguration of its new Good Manufacturing Practices (GMP) facility located in Munich, Germany. This advanced site, situated in Taufkirchen, is set to enhance Minaris' global manufacturing capabilities and solidify its position as a premier partner for innovative therapies, particularly in the realm of cell and gene therapies.

The facility's establishment is a strategic move to further Minaris’ mission of supporting therapy developers as they navigate the complex path from conceptualization to commercialization. With over a decade of expertise in manufacturing advanced therapies, the new site embodies a critical expansion that will bolster Minaris' operations across Europe.

Features and Advantages of the New Facility

The state-of-the-art facility boasts several advanced features tailored to meet the evolving demands of the biopharmaceutical landscape:

• - Six Cleanrooms: The facility includes six Grade B/A cleanrooms dedicated to aseptic manufacturing processes. There is also a Grade C cleanroom specifically designed for bioreactors, which can be converted for higher grades when necessary.
• - Customizable Configurations: With 224 square meters of expandable space, the cleanroom setups can be adapted to accommodate various manufacturing needs, ensuring flexibility in operations.
• - Independent HVAC Systems: Each cleanroom suite is equipped with independently controlled heating, ventilation, and air conditioning systems. This innovation significantly reduces downtime, allowing for simultaneous production activities.
• - Dedicated Laboratories: The facility encompasses specialized process development and quality control labs, enhancing the overall efficiency of testing and manufacturing procedures.
• - Cryopreservation and Safety Systems: Minaris has incorporated advanced cryopreservation facilities and enhanced safety systems, ensuring the integrity of sensitive biological samples and manufacturing processes.

A Vision for the Future

Dr. Orla Cloak, CEO of Minaris Advanced Therapies, emphasized the importance of this facility in advancing cell and gene therapy developments globally. She remarked, “The opening of this facility marks an important milestone in our mission to accelerate the development and manufacturing of transformative cell and gene therapies globally. It enhances our European footprint and enhances our ability to meet client needs with speed, quality, and scalability.”

The Chairman of the Board, Iain Baird, echoed Dr. Cloak’s sentiments, highlighting that this facility is a realization of their shared vision for the future of cell and gene therapy manufacturing—one that is scalable and globally integrated.

The official opening ceremony, which took place on July 31, was a celebration of the team's hard work and commitment to meeting the growing needs of clients and patients around the world.

About Minaris Advanced Therapies

Headquartered in Philadelphia, Pennsylvania, Minaris Advanced Therapies is a leading global contract development and manufacturing organization specializing in cell and gene therapies. The organization operates with more than 650,000 square feet of infrastructure spread across the United States, Europe, and Asia. Minaris prides itself on having manufactured and released over 7,500 GMP batches, playing a pivotal role in supporting therapy innovators from early development stages through clinical trials and finally, to commercial manufacturing.

With the establishment of this new facility, Minaris not only reaffirms its dedication to advancing therapeutic technologies but also strengthens its commitment to creating lasting value for clients and patients on a global scale. As the biotechnology sector continues to evolve at a rapid pace, Minaris remains at the forefront, poised to make significant contributions to the field of advanced therapies through innovation and excellence in service delivery.

About Altaris

Minaris Advanced Therapies is part of the Altaris portfolio, an investment firm focused solely on acquiring and developing companies within the healthcare sector. Since its founding in 2003, Altaris has invested in more than 50 healthcare companies, always striving for excellence and value creation in the healthcare ecosystem.

For more information on Minaris Advanced Therapies and its ongoing developments, visit Minaris Advanced Therapies.